MAP1LC3A and cancer: Compounds were validated by mass spectrometry of the GFP–LC3–YFP reporter and a fluorescent peptide, demonstrating that compound LV-320 inhibits LC3 processing and autophagy in cancer cells and in the liver of GFP–LC3 transgenic mice in vivo.